University of PardubiceFaculty of Chemical Technology

University

Employees
|
Students
Česky

Publication detail

New approach to the safer pharmaceutical treatment of IBD and nephrotoxicity of 5-aminosalicylates

Authors: Roušar Tomáš

Year: 2018

Type of publication: ostatní - přednáška nebo poster

Page from-to: nestránkováno

Titles:

Language	Name	Abstract	Keywords
eng	New approach to the safer pharmaceutical treatment of IBD and nephrotoxicity of 5-aminosalicylates	5-Aminosalicylic acid (5-ASA) (mesalamine or mesalazine) and its derivatives (i.e., balsalazide, olsalazine and sulfasalazine) are anti-inflammatory drugs indicated for the treatment of IBD (ulcerative colitis and Crohn´s disease). The number of IBD patients has been increasing in incidence and prevalence with the highest rates in USA (1.6 mil. only in US), Canada, and Europe. 70k new cases of IBD have been diagnosed in US every year in adults and 80k in children. More than 88% of all UC patients receive treatment with 5-ASA in USA as well as in Europe. The use of these agents in therapy over decades means that long-term toxicity is an important consideration.	5-aminosalicylates; treatment; IBD; nephrotoxicity.